IN8bio Issues Stock Inducement Grant Under Nasdaq Rule 5635(c)(4)
IN8bio has reported an inducement grant to a new employee under Nasdaq Listing Rule 5635(c)(4), a standard mechanism for equity compensation.
IN8bio, a clinical-stage biopharmaceutical company, has disclosed an inducement grant of stock options or equity awards to a newly hired employee, the company announced via GlobeNewswire. The grant was made pursuant to Nasdaq Listing Rule 5635(c)(4), which permits companies listed on the exchange to issue equity compensation as an inducement to prospective employees without requiring prior shareholder approval.
Inducement grants are a common tool among biopharmaceutical firms competing for specialized scientific and executive talent. By structuring equity awards under the Nasdaq exemption, companies can move quickly to close hiring offers without convening a shareholder vote, streamlining the recruitment process for roles that are often critical to ongoing clinical programs.
Read more Maple Finance Partners With IRACE Digital Bank for Fiat Settlement →
IN8bio focuses on the development of gamma-delta T cell therapies for cancer treatment. The company's use of inducement grants reflects broader industry practice of aligning employee interests with long-term corporate performance through equity-based compensation, particularly at clinical-stage firms where cash compensation may be constrained.
The company did not disclose specific terms of the grant, including the number of shares, exercise price, or the identity of the recipient, beyond what is required under applicable Nasdaq rules. Such disclosures are typically made to satisfy the exchange's public notice requirement rather than to provide detailed compensation data.
Continue reading at GlobeNewswire - Industry News on Financial Services.
